Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …

The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of
noninvasive and quantitative technologies capable of monitoring the presence and …

Metastatic osteosarcoma has a poor prognosis with a 2-y, event-free survival rate of∼ 15 to
20%, highlighting the need for the advancement of efficacious therapeutics. Chimeric …

Clinical monitoring of adoptive T cell transfer (ACT) utilizes serial blood analyses to discern
T cell activity. While useful, these data are 1-dimensional and lack spatiotemporal …

Contrast-enhanced MRI is typically used to follow treatment response and progression in
patients with glioblastoma (GBM). However, differentiating tumor progression from …

The past two decades have brought impressive advancements in immune modulation,
particularly with the advent of both cancer immunotherapy and biologic therapeutics for …

Immunotherapy has emerged as a promising alternative in the arsenal against cancer by
harnessing the power of the immune system to specifically target malignant tissues. As the …

Success in solid tumor chimeric antigen receptor (CAR) T-cell therapy requires overcoming
several barriers, including lung sequestration, inefficient accumulation within the tumor, and …

The number of humanized mouse models for the human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS) and other infectious diseases has …